Effects of Remote Cardiac Ischemic Preconditioning

ClinicalTrials.gov ID: NCT06390358

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT06390358. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Acute and Chronic Effects of Tefillin Use on Remote Cardiac Ischemic Preconditioning

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A heart attack occurs when blood flow is disrupted to the heart and is related to both the blockage and flow restoration (reperfusion injury). An occlusion during a heart attack can be cleared (mostly via stents), but there are no methods to decrease reperfusion injury even though animal studies have found that "preconditioning" has powerful protective effects. Through the observation of Jewish men wearing tefillin the investigators have discovered a method of bringing preconditioning to patients at risk for heart attacks. This study will focus on women as the majority of people who wear tefillin (and have been studied) are men.

Study identification

NCT ID: NCT06390358
Recruitment status: Not listed
Study type: Interventional
Phase: Not applicable
Lead sponsor: Jack Rubinstein; Other
Enrollment: 24 participants

Conditions and interventions

Conditions

Cardiac Function and Preconditioning

Interventions

Tefillin Other

Other

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 1, 2024 (Actual)
Primary completion: Apr 1, 2025 (Estimated)
Completion: May 1, 2025 (Estimated)
Last update posted: May 6, 2024

2024 – 2025

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
University of Cincinnati	Cincinnati	Ohio	45267	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06390358, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 6, 2024 · Synced Nov 14, 2026